GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
== Pores == The pore media of the resin particles is one of the most important parameters for the efficiency of the product. These pores make different functions depending on their sizes and are the main feature responsible for the mass transfer between phases making the whole ion exchange process possible. There are three main types of pore sizes:
centrifuge A device used to separate substances based on size, shape, and density by centrifugation, or the rotation of vessels containing the substances around a centred axis at extremely high velocities.
For voluntary service to St John Ambulance in London. Bronagh Mary Hegarty. Covid-19 Principal Pharmacist for Patient Services and Procurement, Western Health and Social Care Trust. For services to Healthcare and Pharmacy. Ian Bruce Henderson. Councillor, Kensington and Chelsea London Borough Council. For services to the community in the Royal Borough of Kensington and Chelsea. Jacqueline Ann Hendra. Social Care Assessor, Devon County Council. For services to People with Disabilities. Robert Patrick Hendry. Custodian, Prime Minister's Office. For services to the Prime Minister's Office. Daniel Herman. For services to Education and to Holocaust Awareness. Timothy John Hewer. For services to Beekeeping in Little Stoke, South Gloucestershire. Pauline Higgins. For services to the community in Liverpool, Merseyside. Donald Alexander Hill. For services to the community in County Londonderry. Felicity Ann De Grave Hills. For services to the community in Hastings, East Sussex. Andrew Richard Hinchliff. Lately Member, Conwy County Council. For services to Local Government and to the community in North Wales. Duncan Holden. Cricket Co-ordinator and Safeguarding Officer, Stoke Newington Cricket Club. For services to Sport in London. Ian Watson Holland. Lately Chair and Trustee, Enable Ayr and District SCIO. For services to People with Learning Disabilities in Ayr and Prestwick. Beverly Joan Hopkins. Special Educational Needs Co-ordinator, Palmerston Primary School, Barry. For services to Education, to People with Disabilities and to Sport. The Reverend Christopher Stewart Howson.
Sources: en.wikipedia.org
The compound is now under active investigation by researchers at NIMH for potential clinical use, and it is hoped that use of HNK instead will mitigate the various concerns (such as abuse and dissociation) of using ketamine itself in the treatment of depression.
=== Swine Flu Outbreak === In 2009, Hetero established Hetero Biopharma, a dedicated R&D unit, and set up a biological manufacturing unit in Hyderabad and quickly became a manufacturer of affordable biosimilars. In the same year, Hetero garnered widespread attention for its public health emergency response capabilities during the Swine Flu outbreak. As various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir. Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009, and shipped about 80 million doses to over 60 countries.Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009. 2014-2019 In 2014, Hetero launched the blockbuster drug Sofosbuvir, a direct-acting antiviral used for the treatment of Hepatitis C, with approval from Gilead Sciences. The drug was marketed and sold in 90 countries, including India, Asia Pacific, Sub-Saharan Africa and other least developed countries, making it accessible at a substantially lower cost to patients. In 2015, Hetero took a step further in Hep C care by becoming the first company in India to launch the fixed-dose combination of Ledipasvir+ Sofosbuvir, used in the treatment of chronic hepatitis genotype 1 in both treatment –naïve and treatment experienced patients.
== External links == Ernest Beutler (1928–2008) – Profile, including an oral history, from The American Society of Hematology. Scientific Publications – All publications of articles by Ernest Beutler listed in PubMed. Marshall A. Lichtman, "Ernest Beutler", Biographical Memoirs of the National Academy of Sciences (2012)
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.